Embracing model-based designs for dose-finding trials
Sharon Love, Sarah Brown, Christopher John Weir et al. · British Journal of Cancer · 2017
BACKGROUND: Dose-finding trials are essential to drug development as they establish recommended doses for later-phase testing. We aim to motivate wider use of model-based designs for dose finding, such as the continual reassessment method (CRM). METHODS: We carried out a literature review of dose-finding designs and conducted a survey to identify perceived barriers to their implementation. RESULTS: We describe the benefits of model-based designs (flexibility, superior operating characteristics, extended scope), their current uptake, and existing resources. The most prominent barriers to implementation of a model-based design were lack of suitable training, chief investigators' preference for algorithm-based designs (e.g., 3+3), and limited resources for study design before funding. We use a real-world example to illustrate how these barriers can be overcome. CONCLUSIONS: There is overwhelming evidence for the benefits of CRM. Many leading pharmaceutical companies routinely implement model-based designs. Our analysis identified barriers for academic statisticians and clinical academics in mirroring the progress industry has made in trial design. Unified support from funders, regulators, and journal editors could result in more accurate doses for later-phase testing, and increase the efficiency and success of clinical drug development. We give recommendations for increasing the uptake of model-based designs for dose-finding trials in academia.
Cited by 65 works. doi:10.1038/bjc.2017.186 Open-access PDF
Authors
- Sharon Love
- Sarah Brown
- Christopher John Weir
- Chris G. Harbron
- Christina Yap
- Birgit Gaschler‐Markefski
- James Matcham
- Louise Caffrey
- Christopher McKevitt
- Sally Clive
- Charles Craddock
- James F. Spicer
- Victoria R. Cornelius
References
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- Cancer phase I clinical trials: efficient dose escalation with overdose control
- A comparison of two phase I trial designs
- Dose Escalation Methods in Phase I Cancer Clinical Trials
- Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
- Critical aspects of the Bayesian approach to phase I cancer trials
- Maintenance therapy with low‐dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome
- Translation of Innovative Designs Into Phase I Trials
- A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies
- The continual reassessment method for dose-finding studies: a tutorial